Pierre Nahon

13.4k total citations · 5 hit papers
147 papers, 5.4k citations indexed

About

Pierre Nahon is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Pierre Nahon has authored 147 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Epidemiology, 93 papers in Hepatology and 26 papers in Molecular Biology. Recurrent topics in Pierre Nahon's work include Liver Disease Diagnosis and Treatment (96 papers), Hepatocellular Carcinoma Treatment and Prognosis (51 papers) and Liver Disease and Transplantation (46 papers). Pierre Nahon is often cited by papers focused on Liver Disease Diagnosis and Treatment (96 papers), Hepatocellular Carcinoma Treatment and Prognosis (51 papers) and Liver Disease and Transplantation (46 papers). Pierre Nahon collaborates with scholars based in France, United States and Italy. Pierre Nahon's co-authors include Nathalie Ganne‐Carrié, Amit G. Singal, Pietro Lampertico, Michel Beaugrand, Jessica Zucman‐Rossi, Olivier Séror, Jean‐Charles Nault, Marianne Ziol, Jean–Claude Trinchet and Roland Amathieu and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Pierre Nahon

140 papers receiving 5.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology and surveillance for hepatocellular carcinoma: New trends

2020 740 citations Amit G. Singal, Pierre Nahon et al. Journal of Hepatology profile →
PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters

2014 512 citations Mohamed N. Triba, Laurence Le Moyec et al. Molecular BioSystems profile →
Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations

2017 293 citations Jean‐Charles Nault, Olivier Sutter et al. Journal of Hepatology profile →
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

2022 246 citations Amit G. Singal, Nicole E. Rich et al. Journal of Hepatology profile →
Hepatocellular carcinoma in the setting of alcohol-related liver disease

2019 245 citations Nathalie Ganne‐Carrié, Pierre Nahon Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre Nahon France	35	2.8k	2.6k	1.3k	682	646	147	5.4k
Yong‐Han Paik South Korea	37	3.7k 1.3×	3.7k 1.4×	1.4k 1.0×	437 0.6×	527 0.8×	144	6.4k
Hironori Koga Japan	39	1.7k 0.6×	1.8k 0.7×	1.7k 1.3×	524 0.8×	1.0k 1.6×	155	5.3k
Hong Ren China	38	2.2k 0.8×	1.8k 0.7×	1.4k 1.0×	285 0.4×	512 0.8×	310	5.4k
Yoshikazu Murawaki Japan	35	1.7k 0.6×	1.8k 0.7×	1.0k 0.8×	339 0.5×	528 0.8×	196	4.1k
Takuji Torimura Japan	45	3.4k 1.2×	3.3k 1.3×	1.7k 1.3×	1.0k 1.5×	1.2k 1.9×	282	7.6k
Hayato Nakagawa Japan	38	1.9k 0.7×	1.9k 0.7×	2.1k 1.6×	412 0.6×	1.4k 2.1×	178	6.1k
Makoto Nakamuta Japan	42	3.6k 1.3×	2.2k 0.9×	1.9k 1.4×	408 0.6×	721 1.1×	217	6.6k
Alexander Wree Germany	35	3.5k 1.2×	1.5k 0.6×	2.6k 2.0×	296 0.4×	416 0.6×	90	6.0k
Helen L. Reeves United Kingdom	36	4.6k 1.6×	4.0k 1.5×	2.2k 1.7×	667 1.0×	1.3k 2.0×	95	8.3k
Pierre Brissot France	57	1.6k 0.6×	1.0k 0.4×	1.3k 1.0×	489 0.7×	576 0.9×	305	12.1k

Countries citing papers authored by Pierre Nahon

Since Specialization

Citations

This map shows the geographic impact of Pierre Nahon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Nahon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Nahon more than expected).

Fields of papers citing papers by Pierre Nahon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Nahon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Nahon. The network helps show where Pierre Nahon may publish in the future.

Co-authorship network of co-authors of Pierre Nahon

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Nahon. A scholar is included among the top collaborators of Pierre Nahon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Nahon. Pierre Nahon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paisant, Anita, Agnès Rode, Riccardo Sartoris, et al.. (2025). Improving risk stratification and detection of early HCC using ultrasound-based deep learning models. JHEP Reports. 7(10). 101510–101510.

Manneville, Florian, Léopold Fezeu, Alice Bellicha, et al.. (2025). Associations between fruit and vegetable consumption and HCC occurrence in patients with cirrhosis. JHEP Reports. 7(5). 101355–101355.

Blaise, Lorraine, Marianne Ziol, Claudia Campani, et al.. (2025). Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma. JHEP Reports. 7(9). 101430–101430. 1 indexed citations

Campani, Claudia, Sandrine Imbeaud, Gabrielle Couchy, et al.. (2024). Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Gut. 73(11). 1870–1882. 21 indexed citations

Campani, Claudia, D C Pallas, Όλγα Γιουλεμέ, et al.. (2024). Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies. JHEP Reports. 6(11). 101190–101190. 2 indexed citations

Singal, Amit G., Marco Sanduzzi‐Zamparelli, Pierre Nahon, et al.. (2023). International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance. Journal of Hepatology. 79(1). 226–239. 51 indexed citations

Nahon, Pierre, et al.. (2023). Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLoS ONE. 18(1). e0280442–e0280442. 8 indexed citations

Campani, Claudia, Manon Allaire, Philippe Sultanik, et al.. (2023). Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab. Hepatology. 79(1). 49–60. 14 indexed citations

Laurent‐Puig, Pierre, Marianne Ziol, Nathalie Ganne‐Carrié, et al.. (2023). Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab. Journal of Hepatology. 79(6). 1450–1458. 29 indexed citations

10.

Campani, Claudia, Sandrine Imbeaud, Marianne Ziol, et al.. (2023). Dynamic evolution of circulating tumor DNA in patients with hepatocellular carcinoma across tumor stages and treatments. Digestive and Liver Disease. 55. S213–S214. 1 indexed citations

11.

Retat, Lise, Peter Jepsen, Alexander M. Martin, et al.. (2023). Preventing liver disease with policy measures to tackle alcohol consumption and obesity: The HEPAHEALTH II study. Journal of Hepatology. 80(4). 543–552. 17 indexed citations

12.

Sutton, Angéla, Lorraine Blaise, Olivier Séror, et al.. (2022). Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 9. 1369–1383. 2 indexed citations

13.

Nahon, Pierre, Richard Layese, Carole Cagnot, et al.. (2021). HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management. Cancer Prevention Research. 14(5). 581–592. 1 indexed citations

14.

Nahon, Pierre, Christophe Aubé, Lucile Moga, et al.. (2021). Non-invasive diagnosis and follow-up of primary malignant liver tumours. Clinics and Research in Hepatology and Gastroenterology. 46(1). 101766–101766. 2 indexed citations

15.

Gelu‐Siméon, Moana, M. Lewin, Maria A. Ostos, et al.. (2018). Prognostic factors of survival in HIV/HCV co‐infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort. Liver International. 39(1). 136–146. 11 indexed citations

16.

Bastard, Jean‐Philippe, Soraya Fellahi, Étienne Audureau, et al.. (2018). Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis. European Cytokine Network. 29(3). 112–120. 7 indexed citations

17.

Triba, Mohamed N., Laurence Le Moyec, Roland Amathieu, et al.. (2014). PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters. Molecular BioSystems. 11(1). 13–19. 512 indexed citations breakdown →

18.

Nault, Jean‐Charles, Erwan Guyot, Christelle Laguillier, et al.. (2013). Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. Cancer Epidemiology Biomarkers & Prevention. 22(8). 1343–1352. 65 indexed citations

19.

Nahon, Pierre, Roland Amathieu, Mohamed N. Triba, et al.. (2012). Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. Clinical Cancer Research. 18(24). 6714–6722. 64 indexed citations

20.

Nahon, Pierre, Angéla Sutton, Pierre Rufat, et al.. (2009). Myeloperoxidase and superoxide dismutase 2 polymorphisms comodulate the risk of hepatocellular carcinoma and death in alcoholic cirrhosis #. Hepatology. 50(5). 1484–1493. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact